Farzad Sabet, MD
Physical Medicine & Rehabilitation · Redding, CANPI 1164454591
Payments from drug & device makers
Across 66 payments — averaging $21.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$275
- Nevro Corp.$171
- Merz Pharmaceuticals, LLC$171
- Si-bone, Inc.$149
- Amgen$137
- Boston Scientific$115
- plus $388 from 11 others
What the payments were for
- Food & beverage$1,405100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 14 | $275 |
| Nevro Corp. | 10 | $171 |
| Merz Pharmaceuticals, LLC | 4 | $171 |
| Si-bone, Inc. | 3 | $149 |
| Amgen | 6 | $137 |
| Boston Scientific | 6 | $115 |
| Assertio Therapeutics, Inc. | 5 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Pfizer | 4 | $65 |
| Biohaven Pharmaceuticals, Inc. | 3 | $61 |
| Vertex | 1 | $24 |
| Avanos Medical | 1 | $19 |
| Abbott | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| Baudax Bio Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $13 |
| Pacira Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iFuse Implant$107
How this compares
$1,405 in reported general payments places this provider in the 75th percentile of 830 physical medicine & rehabilitation providers in California.
See all physical medicine & rehabilitation providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 36 | $727 |
| Alprazolam | 560 | $593 |
| Celecoxib | 11 | $490 |
| Duloxetine Hcl | 64 | $487 |
| Pregabalin | 17 | $401 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 161 | $206 |
| Tramadol Hcl | 15 | $90 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Redding
- Ziyad AyyoubParamount$1.8M
- John ShenFontana$1.3M
- Andrew SkalskySan Diego$463K
- Nanette JoyceSacramento$237K
- Mary OatesSanta Maria$158K
- Jeryl WiensFresno$125K
- Pratik GandhiAnaheim$122K
- Ronald SchillingLong Beach$113K
- Kevin BarretteSan Francisco$84K
- Jeffrey ChenSan Diego$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.